Labomed is delighted to announce that the European Patent Office has granted the European Patent EP3845215B1 covering the Lisdexamfetamine Oral Solution. The product has been developed by Labomed and sponsored by Labomed, Pharma-Data S.A. and Adalvo.
This patent will provide the aforementioned parties protection to their value-added version of Lisdexamfetamine. The product comes in the form of a taste-masked, ready-to-use oral solution, being a child-friendly, re-purposed version of Elvanse® – a CNS drug indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The brand (together with its US sister-brand that is called Vyvanse®) currently sells over $4 billion across the globe.
In addition to the European Patent, our patent has been filed in US and other regions to protect our unique development.
